Alzheimer’s, 2 psychiatric drugs slow progression

The University of Colorado Medical Campus research team was interested in finding drugs that could block the protein Apolipoprotein E4 (ApoE4)which they speculate could reduce the chances of developmentAlzheimer

While examining the medicines that this could have an effect, the team noted that two of the drugs are commonly prescribed for: psychiatric disorders The drugs were imipramine and olanzapine; imipramine is a tricyclic antidepressant and olanzapine is an antipsychotic.

We then went through the huge database of the National Alzheimer’s Coordination Center and asked what happened if someone was prescribed these drugs for normal indications, but they were Alzheimer’s patients. People who received these drugs developed better cognition and even improved in their clinical diagnosis. Compared to those who did not take these drugs, they returned from Alzheimer’s disease to mild cognitive impairment or mild cognitive impairment to normal.

Huntington Potter, Ph.D., professor of neurology and director of the CU Alzheimer’s and Cognition Center, Colorado

Potter and his team noted that compared to other antidepressants and antipsychotics, Alzheimer’s patients taking imipramine and olanzapine saw that cognitive improvements that can help reverse the progression of the disease.

The researchers then examined the patients to see if there is a difference in how men and women respond to the cumulative effects of taking. imipramine Their calculations showed that men between the ages of 66.5 and 88.5 had the greatest benefits.

The authors wrote that long-term use of imipramine improves the clinical diagnosis for men. Although women also saw improvement, the authors note that it is less prominent than men.